#yestoKalydeco

Screen Shot 2014-08-19 at 5.59.05 PM

Cystic  fibrosis community
with  gating  (class  III)  mutations
can  now  breathe  easy  on  news  of  Government  subsidy
Australia’s  cystic  fibrosis  community  is  elated
by  the  news of  expanded  PBS  subsidy  for  Kalydeco  in  people  aged  6  years  and  older  who  have gating  (class  III)  mutations  in  the  cystic  fibrosis  transmembrane
conductance  regulator  (CFTR)  gene.
Kalydeco  has  been  approved  for  PBS  subsidy  from  01  December  2014  for  people  6  years  and  older  who  have  the  following  gating  mutations:  G551D,  G178R,  S549N,
S549R,  G551S,  G1244E,  S1251N,  S1255P,  G970R  and  G1349D.  Kalydeco  the  most  important  development  in  the  treatment  of  the  disease  since  the  discovery  of  the cystic  fibrosis  gene in  1989  works  by  ‘turning  off’  the  genetic  defect  that  causes  cystic  fibrosis,  allowing  the  body  to  break  down  and  drain  mucus  in  the  lungs  and  digestive  system.KALYDECO  will  be  listed  on  the  PBS  under  section  100,  Complex  Authority  Required  Highly  Specialised  Drugs  Program
*  People  must  be  aged  six  years  and  older  to  receive Kalydeco.

 

 

Tell us what you think

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s